Characteristics of the study cohort
| Characteristics . | N . | Total population, N (%) . | . | Without skin involvement, n (%) . | . | With skin involvement, n (%) . | P . |
|---|---|---|---|---|---|---|---|
| Participating sites, no. (%) | 458 | 207 | 250* | .002 | |||
| Fred Hutchinson Cancer Research Center | 214 (46) | 95 (46) | 118 (47) | ||||
| Stanford University Medical Center | 65 (14) | 30 (14) | 35 (14) | ||||
| Dana-Farber Cancer Institute | 53 (12) | 17 (8) | 36 (14) | ||||
| University of Minnesota | 51 (11) | 34 (16) | 17 (7) | ||||
| Vanderbilt University Medical Center | 36 (8) | 17 (8) | 19 (8) | ||||
| Medical College of Wisconsin | 15 (3) | 1 (1) | 14 (6) | ||||
| Northwestern Children's Hospital | 13 (3) | 8 (4) | 5 (2) | ||||
| Moffitt Cancer Center | 8 (2) | 4 (2) | 4 (2) | ||||
| Washington University Medical Center | 3 (1) | 1 (1) | 2 (1) | ||||
| Case type, no. (%) | 458 | 207 | 250 | .62 | |||
| Incident | 254 (55) | 112 (54) | 141 (56) | ||||
| Prevalent | 204 (45) | 95 (46) | 109 (44) | ||||
| Patient age, y, no. (%) | 458 | 207 | 250 | .32 | |||
| 18 or younger | 14 (3) | 8 (4) | 6 (2) | ||||
| 19-49 | 194 (42) | 93 (45) | 100 (40) | ||||
| 50 or older | 250 (55) | 106 (51) | 144 (58) | ||||
| Patient sex, no. (%) | 458 | 207 | 250 | .03 | |||
| Male | 264 (58) | 108 (52) | 155 (62) | ||||
| Female | 194 (42) | 99 (48) | 95 (38) | ||||
| Race, no. (%) | 458 | 207 | 250 | < .001 | |||
| White | 411 (90) | 175 (85) | 235 (94) | ||||
| Nonwhite | 47 (10) | 32 (15) | 15 (6) | ||||
| Transplantation stem cell source, no. (%) | 458 | 207 | 250 | .01 | |||
| Peripheral blood | 402 (88) | 171 (83) | 230 (92) | ||||
| Bone marrow | 34 (7) | 22 (11) | 12 (5) | ||||
| Cord blood | 22 (5) | 14 (7) | 8 (3) | ||||
| Transplantation conditioning type | 457 | 207 | 249 | .99 | |||
| Myeloablative | 260 (57) | 118 (57) | 142 (57) | ||||
| Not myeloablative | 197 (43) | 89 (43) | 107 (43) | ||||
| Donor type, no. (%) | 457 | 207 | 249 | .74 | |||
| HLA-identical related | 202 (45) | 91 (44) | 111 (45) | ||||
| HLA-matched unrelated | 180 (39) | 79 (38) | 100 (40) | ||||
| HLA-mismatched | 75 (16) | 37 (18) | 38 (15) | ||||
| Donor sex, no. (%) | 453 | 205 | 247 | .06 | |||
| Female into male | 130 (29) | 50 (24) | 80 (32) | ||||
| Other | 323 (71) | 155 (76) | 167 (68) | ||||
| Prior acute GVHD, no. (%) | 458 | 207 | 250 | .28 | |||
| Prior acute GVHD | 311 (68) | 135 (65) | 175 (70) | ||||
| No prior acute GVHD | 147 (32) | 72 (35) | 75 (30) | ||||
| Median months from transplantation to enrollment (range) | 458 | 12.2 (3-299) | 207 | 12.1 (3-299) | 250 | 12.6 (3-39) | .95 |
| Characteristics . | N . | Total population, N (%) . | . | Without skin involvement, n (%) . | . | With skin involvement, n (%) . | P . |
|---|---|---|---|---|---|---|---|
| Participating sites, no. (%) | 458 | 207 | 250* | .002 | |||
| Fred Hutchinson Cancer Research Center | 214 (46) | 95 (46) | 118 (47) | ||||
| Stanford University Medical Center | 65 (14) | 30 (14) | 35 (14) | ||||
| Dana-Farber Cancer Institute | 53 (12) | 17 (8) | 36 (14) | ||||
| University of Minnesota | 51 (11) | 34 (16) | 17 (7) | ||||
| Vanderbilt University Medical Center | 36 (8) | 17 (8) | 19 (8) | ||||
| Medical College of Wisconsin | 15 (3) | 1 (1) | 14 (6) | ||||
| Northwestern Children's Hospital | 13 (3) | 8 (4) | 5 (2) | ||||
| Moffitt Cancer Center | 8 (2) | 4 (2) | 4 (2) | ||||
| Washington University Medical Center | 3 (1) | 1 (1) | 2 (1) | ||||
| Case type, no. (%) | 458 | 207 | 250 | .62 | |||
| Incident | 254 (55) | 112 (54) | 141 (56) | ||||
| Prevalent | 204 (45) | 95 (46) | 109 (44) | ||||
| Patient age, y, no. (%) | 458 | 207 | 250 | .32 | |||
| 18 or younger | 14 (3) | 8 (4) | 6 (2) | ||||
| 19-49 | 194 (42) | 93 (45) | 100 (40) | ||||
| 50 or older | 250 (55) | 106 (51) | 144 (58) | ||||
| Patient sex, no. (%) | 458 | 207 | 250 | .03 | |||
| Male | 264 (58) | 108 (52) | 155 (62) | ||||
| Female | 194 (42) | 99 (48) | 95 (38) | ||||
| Race, no. (%) | 458 | 207 | 250 | < .001 | |||
| White | 411 (90) | 175 (85) | 235 (94) | ||||
| Nonwhite | 47 (10) | 32 (15) | 15 (6) | ||||
| Transplantation stem cell source, no. (%) | 458 | 207 | 250 | .01 | |||
| Peripheral blood | 402 (88) | 171 (83) | 230 (92) | ||||
| Bone marrow | 34 (7) | 22 (11) | 12 (5) | ||||
| Cord blood | 22 (5) | 14 (7) | 8 (3) | ||||
| Transplantation conditioning type | 457 | 207 | 249 | .99 | |||
| Myeloablative | 260 (57) | 118 (57) | 142 (57) | ||||
| Not myeloablative | 197 (43) | 89 (43) | 107 (43) | ||||
| Donor type, no. (%) | 457 | 207 | 249 | .74 | |||
| HLA-identical related | 202 (45) | 91 (44) | 111 (45) | ||||
| HLA-matched unrelated | 180 (39) | 79 (38) | 100 (40) | ||||
| HLA-mismatched | 75 (16) | 37 (18) | 38 (15) | ||||
| Donor sex, no. (%) | 453 | 205 | 247 | .06 | |||
| Female into male | 130 (29) | 50 (24) | 80 (32) | ||||
| Other | 323 (71) | 155 (76) | 167 (68) | ||||
| Prior acute GVHD, no. (%) | 458 | 207 | 250 | .28 | |||
| Prior acute GVHD | 311 (68) | 135 (65) | 175 (70) | ||||
| No prior acute GVHD | 147 (32) | 72 (35) | 75 (30) | ||||
| Median months from transplantation to enrollment (range) | 458 | 12.2 (3-299) | 207 | 12.1 (3-299) | 250 | 12.6 (3-39) | .95 |
One patient missing the National Institutes of Health (NIH) skin response measure.